BESREMi® Canada Approval
Health Canada Approves PharmaEssentia's BESREMi® as New Polycythemia Vera Treatment
Health Canada has approved BESREMi® (ropeginterferon alfa-2b), a new treatment for adults with polycythemia vera (PV), a rare and chronic blood cancer, according to Financial Post. The approval was granted to FORUS Therapeutics Inc., the Canadian subsidiary of Taiwan-based PharmaEssentia Corporation, through a Notice of Compliance (NOC).
BESREMi® is expected to reach Canadian pharmacies and clinics within weeks. PV is a serious condition that forces the body to produce too many blood cells. Left untreated, it can lead to blood clots, stroke, heart attack, and even leukemia.
What Polycythemia Vera Does to the Body
Polycythemia vera is a rare blood cancer caused by a genetic mutation. It makes the bone marrow produce too many red blood cells. This thickens the blood and raises the risk of dangerous clots. Patients face life-threatening risks including stroke, heart attack, and progression to leukemia, Montreal Gazette reported.
PV is a chronic, lifelong disease with no widely available cure. Patients require ongoing treatment to control blood cell counts and reduce the risk of serious complications. Until now, treatment options in Canada were limited.
How BESREMi Works and Why It Stands Out
BESREMi is a type of drug called a pegylated interferon. It works by targeting the abnormal cells that drive PV at a molecular level. Unlike older treatments that simply reduce blood cell counts, BESREMi aims to slow the disease at its source, according to Owen Sound Sun Times.
The drug is given as a single injection every two weeks. That less frequent dosing schedule sets it apart from some existing therapies. Clinical data showed patients achieved hematocrit control — meaning their blood thickness returned to safer levels — and some saw molecular remission, a deep biological response.
PharmaEssentia's Growing Footprint Beyond Taiwan
PharmaEssentia is listed on the Taiwan Stock Exchange (TWSE: 6446) and built its reputation around BESREMi. The drug was first approved in Europe in 2019 and in the United States in 2021. The Canadian approval marks another step in the company's global expansion, Northern News reported.
The company operates in Canada through its wholly owned subsidiary FORUS Therapeutics Inc. That local structure is designed to help PharmaEssentia navigate Canadian regulatory and commercial channels more effectively as it prepares for the drug's launch.
Canadian PV Patients Set to Gain a New Option
The approval is a meaningful win for Canadian patients living with PV, a disease that affects only a small fraction of the population. Rare disease patients often wait years for new treatments to reach Canada after approvals elsewhere. BESREMi's Canadian launch, expected within weeks, closes that gap, according to Fort Saskatchewan Record.
Physicians treating PV in Canada will now have a scientifically distinct option to offer patients, especially those who have not responded well to standard therapies like hydroxyurea. Expanded treatment choices can help doctors tailor care more closely to each patient's needs.
Sentiment
NeutralPublishers
11
Articles
11
Reach
11
